Sumitomo Dainippon Pharma Co., Ltd. CEO Net Worth

Last Updated Mar 10, 2025
CEO NameHiroshi Nomura
NationalityJapan
Net Worth Estimation$5 million

Hiroshi Nomura's estimated net worth of around $5 million USD stems primarily from his executive compensation, stock ownership, and performance incentives at Sumitomo Dainippon Pharma Co., Ltd. as CEO. The figure aggregates reported salary, bonuses, and relevant shares or options according to publicly available financial disclosures and industry comparables.

Hiroshi Nomura's estimated net worth of $5 million is 5% of the maximum and 50% of the minimum estimated CEO net worths in the healthcare business category. His net worth is below both the $10 million minimum and $90 million maximum benchmarks for healthcare CEOs.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Hiroshi Nomura Performance in Sumitomo Dainippon Pharma Co., Ltd.

Hiroshi Nomura, CEO of Sumitomo Dainippon Pharma Co., Ltd., demonstrates strong leadership by driving innovation and strategic global expansion in the pharmaceutical sector. His decision-making emphasizes R&D investment and partnership development, enhancing the company's drug pipeline and market presence. Under his leadership, Sumitomo Dainippon Pharma has strengthened its competitive position and achieved significant growth in performance and shareholder value.


Latest News

Sumitomo Dainippon Pharma Co., Ltd. Advances Digital Therapeutics with BehaVR Partnership

Sumitomo Dainippon Pharma, led by CEO Hiroshi Nomura, has announced a landmark deal with BehaVR to develop and commercialize prescription digital therapeutics and wellness products, focusing on innovative solutions for mental health and chronic disease management. The collaboration highlights the company's commitment to expanding beyond traditional pharmaceuticals into digital health and regenerative medicine.
Source: http://www.prnewswire.com/news-releases/sumitomo-dainippon-pharma-and-behavr-announce-landmark-deal-for-multiple-virtual-reality-digital-therapeutics-301401488.html



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Sumitomo Dainippon Pharma Co., Ltd. are subject to change from time to time.

Comments

No comment yet